These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 28105902)

  • 1. Cost-effectiveness of using adjunctive porcine small intestine submucosa tri-layer matrix compared with standard care in managing diabetic foot ulcers in the US.
    Guest JF; Weidlich D; Singh H; La Fontaine J; Garrett A; Abularrage CJ; Waycaster CR
    J Wound Care; 2017 Jan; 26(Sup1):S12-S24. PubMed ID: 28105902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential cost-effectiveness of using adjunctive dehydrated human amnion/chorion membrane allograft in the management of non-healing diabetic foot ulcers in the United Kingdom.
    Guest JF; Atkin L; Aitkins C
    Int Wound J; 2021 Dec; 18(6):889-901. PubMed ID: 33827144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential cost-effectiveness of using a collagen-containing dressing in managing diabetic foot ulcers in the UK.
    Guest JF; Singh H; Vowden P
    J Wound Care; 2018 Mar; 27(3):136-144. PubMed ID: 29509110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Cost-Effectiveness Analysis Comparing Single-use and Traditional Negative Pressure Wound Therapy to Treat Chronic Venous and Diabetic Foot Ulcers.
    Kirsner RS; Delhougne G; Searle RJ
    Wound Manag Prev; 2020 Mar; 66(3):30-36. PubMed ID: 32294054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Skin Substitutes for Adults With Diabetic Foot Ulcers and Venous Leg Ulcers: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2021; 21(7):1-165. PubMed ID: 34211616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cost-effectiveness of treating diabetic lower extremity ulcers with becaplermin (Regranex): a core model with an application using Swedish cost data.
    Persson U; Willis M; Odegaard K; Apelqvist J
    Value Health; 2000; 3 Suppl 1():39-46. PubMed ID: 16464208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Wound closure in patients with DFU: a cost-effectiveness analysis of two cellular/tissue-derived products.
    Gilligan AM; Waycaster CR; Landsman AL
    J Wound Care; 2015 Mar; 24(3):149-56. PubMed ID: 25764960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative analysis of skin substitutes used in the management of diabetic foot ulcers.
    Martinson M; Martinson N
    J Wound Care; 2016 Oct; 25(Sup10):S8-S17. PubMed ID: 27681811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effective management of recalcitrant diabetic foot ulcers.
    Albert S
    Clin Podiatr Med Surg; 2002 Oct; 19(4):483-91. PubMed ID: 12471856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness modeling of Dermagraft for the treatment of diabetic foot ulcers in the french context.
    Allenet B; Parée F; Lebrun T; Carr L; Posnett J; Martini J; Yvon C
    Diabetes Metab; 2000 Apr; 26(2):125-32. PubMed ID: 10804327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of tissue engineering products for the management of neuropathic diabetic foot ulcers: an interim analysis.
    Frykberg RG; Cazzell SM; Arroyo-Rivera J; Tallis A; Reyzelman AM; Saba F; Warren L; Stouch BC; Gilbert TW
    J Wound Care; 2016 Jul; 25(Sup7):S18-S25. PubMed ID: 29027848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Management of Diabetic Foot Ulcers with Porcine Small Intestine Submucosa Tri-Layer Matrix: A Randomized Controlled Trial.
    Cazzell SM; Lange DL; Dickerson JE; Slade HB
    Adv Wound Care (New Rochelle); 2015 Dec; 4(12):711-718. PubMed ID: 26634183
    [No Abstract]   [Full Text] [Related]  

  • 13. Cost effectiveness of Becaplermin in the treatment of diabetic foot ulcers in four European countries.
    Ghatnekar O; Persson U; Willis M; Odegaard K
    Pharmacoeconomics; 2001; 19(7):767-78. PubMed ID: 11548912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Illustration of Cost Saving Implications of Lower Extremity Nerve Decompression to Prevent Recurrence of Diabetic Foot Ulceration.
    Rankin TM; Miller JD; Gruessner AC; Nickerson DS
    J Diabetes Sci Technol; 2015 Jul; 9(4):873-80. PubMed ID: 26055081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cost effectiveness of Apligraf treatment of diabetic foot ulcers.
    Redekop WK; McDonnell J; Verboom P; Lovas K; Kalo Z
    Pharmacoeconomics; 2003; 21(16):1171-83. PubMed ID: 14594438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment options for diabetic neuropathic foot ulcers: a cost-effectiveness analysis.
    Kantor J; Margolis DJ
    Dermatol Surg; 2001 Apr; 27(4):347-51. PubMed ID: 11298704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bilayered bioengineered skin substitute (Apligraf): a review of its use in the treatment of venous leg ulcers and diabetic foot ulcers.
    Curran MP; Plosker GL
    BioDrugs; 2002; 16(6):439-55. PubMed ID: 12463767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic outcomes among Medicare patients receiving bioengineered cellular technologies for treatment of diabetic foot ulcers.
    Rice JB; Desai U; Ristovska L; Cummings AK; Birnbaum HG; Skornicki M; Margolis DJ; Parsons NB
    J Med Econ; 2015; 18(8):586-95. PubMed ID: 25786331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of becaplermin gel on wound healing of diabetic foot ulcers.
    Gilligan AM; Waycaster CR; Motley TA
    Wound Repair Regen; 2015; 23(3):353-60. PubMed ID: 25810233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperbaric Oxygen Therapy for the Treatment of Diabetic Foot Ulcers: A Health Technology Assessment.
    Health Quality Ontario
    Ont Health Technol Assess Ser; 2017; 17(5):1-142. PubMed ID: 28572866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.